Hexylresorcinol
Comparison of the simple cyclic voltammetry (CV) and DPPH assays for the determination of antioxidant capacity of active principles. (1/4)
(+info)Randomised, double-blind, placebo-controlled study of a single dose of an amylmetacresol/2,4-dichlorobenzyl alcohol plus lidocaine lozenge or a hexylresorcinol lozenge for the treatment of acute sore throat due to upper respiratory tract infection. (2/4)
PURPOSE: Sore throat is a frequent reason for seeking medical care but few prescription options are available. Lozenges are effective in delivering active ingredients to the throat. This study was conducted to determine the analgesic efficacy of two lozenges one containing amylmetacresol (AMC)/2,4-dichlorobenzyl alcohol (DCBA) and lidocaine and one containing hexylresorcinol versus placebo in patients with acute sore throat due to upper respiratory tract infection (URTI). METHODS: This was a multicentre, randomised, double-blind, parallel group, placebo-controlled study. In total, 190 patients were randomised 1:1:1 to a single dose of AMC/DCBA + lidocaine, hexylresorcinol or placebo lozenge. Subjective ratings of throat soreness, difficulty swallowing, swollen throat, numbing, and sore throat relief were obtained up to 2 hours post dose. Patient and investigator global ratings and a consumer questionnaire were also collected. The primary endpoint was the change from baseline in severity of throat soreness for both lozenges versus placebo at 2 hours post dose. RESULTS: The hexylresorcinol lozenge demonstrated superiority over placebo for primary and secondary efficacy variables including those related to throat soreness, sore throat relief and difficulty swallowing; the AMC/DCBA + lidocaine lozenge was also superior to placebo for secondary endpoints at various time points but did not reach significance for the primary efficacy variable. Both lozenges had a rapid onset of action from 1-10 minutes post dose for the AMC/DCBA + lidocaine lozenge and 1-5 minutes post dose for the hexylresorcinol lozenge. Numbness was reported from 1 minute post dose with the AMC/DCBA + lidocaine lozenge and was greatest at 15 minutes. Numbness was reported from 5 minutes post dose with the hexylresorcinol lozenge and was greatest at 10 minutes. Both lozenges were well tolerated. CONCLUSIONS: Both AMC/DCBA + lidocaine and hexylresorcinol lozenges provided rapid and effective sore throat relief in patients with URTI. (+info)Application of a novel microtitre plate-based assay for the discovery of new inhibitors of DNA gyrase and DNA topoisomerase VI. (3/4)
(+info)Oxidation of the flavonol fisetin by polyphenol oxidase. (4/4)
The present study demonstrates the antiradical efficiency of fisetin, a flavonol widely distributed in fruits and vegetables, by its ability to react with two different free radicals, ABTS; and DPPH;. The polyphenolic nature of fisetin led us to consider whether it might be oxidised by polyphenol oxidase (PPO), and the results reported show that it can be oxidised by PPO extracted and partially purified from broad bean seeds. The reaction was followed by recording spectral changes with time, with maximal spectral changes being observed at 282 nm (increase in absorbance) and at 362 nm (decrease). The presence of two isosbectic points (at 265 and 304 nm) suggested that only one absorbent product was formed. These spectral changes were not observed in the absence of PPO. The oxidation rate varied with the pH, reaching its highest value at pH 5.5. The fisetin oxidation rate increased in the presence of sodium dodecyl sulfate, an activator of polyphenol oxidase. Maximal activity was obtained at 0.87 mM sodium dodecyl sulfate. The following kinetic parameters were determined: Vmax=49 microM/min, Km=0.6 mM, Vmax/Km=8.2x10-2 min-1. Flavonol oxidation was inhibited by selective PPO inhibitors such as cinnamic acid (a classical competitive inhibitor, Ki=1.4 mM) and 4-hexylresorcinol, which behaved as a slow-binding inhibitor. The results reported show that fisetin oxidation was strictly dependent on the presence of polyphenol oxidase. (+info)Hexylresorcinol is not a medical term per se, but it is a chemical compound that has been used in some medical and cosmetic applications. Here's a definition of Hexylresorcinol from a chemistry perspective:
Hexylresorcinol is an organic compound with the formula (HOC6H4)2CH3. It is a derivative of resorcinol, where two resorcinol molecules are attached to a hexyl group. This aromatic phenolic compound has antiseptic, antibacterial, and analgesic properties, which has led to its use in various medical and consumer products, such as mouthwashes, throat lozenges, and topical creams. It is also used as an antioxidant in food and cosmetic applications.
Please note that while Hexylresorcinol has various uses, it should be handled with care due to its potential toxicity and irritant properties. Always follow the instructions provided by a healthcare professional or manufacturer when using products containing this compound.
Benzyl alcohol is an aromatic alcohol with the chemical formula C6H5CH2OH. It is a colorless liquid with a mild, pleasant odor and is used as a solvent and preservative in cosmetics, medications, and other products. Benzyl alcohol can also be found as a natural component of some essential oils, fruits, and teas.
Benzyl alcohol is not typically considered a "drug" or a medication, but it may have various pharmacological effects when used in certain medical contexts. For example, it has antimicrobial properties and is sometimes used as a preservative in injectable medications to prevent the growth of bacteria and fungi. It can also be used as a local anesthetic or analgesic in some topical creams and ointments.
It's important to note that benzyl alcohol can be harmful or fatal to infants and young children, especially when it is used in high concentrations or when it is introduced into the body through intravenous (IV) routes. Therefore, it should be used with caution in these populations and only under the guidance of a healthcare professional.
4-Hexylresorcinol